<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846274</url>
  </required_header>
  <id_info>
    <org_study_id>SKATIII_I_2007</org_study_id>
    <nct_id>NCT00846274</nct_id>
  </id_info>
  <brief_title>Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III</brief_title>
  <official_title>Single-Dose, Open Label, Randomized Comparative Clinical Trial to Evaluate the Tolerability, Safety and PK/PD of Human ATIII Products, &quot;SKATIII Injection&quot; and&quot;ATIII Injection&quot; in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <brief_summary>
    <textblock>
      To evaluate the PK/PD of single injected human ATIII Products, SKATIII and ATIII, phase1
      study in healthy male subjects was designed
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ATIII activity</measure>
    <time_frame>within 20min after injection ATIII</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ATIII antigen</measure>
    <time_frame>within 20min after injection ATIII</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Antithrombin III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SK Antithrombin III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SK Antithrombin III</intervention_name>
    <arm_group_label>Antithrombin III</arm_group_label>
    <arm_group_label>SK Antithrombin III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 19 to 40

          -  Body weight: More than 50kg

          -  Healthy male subject

        Exclusion Criteria:

          -  Hb&lt;14g/dL, Hct&lt;42%

          -  ATIII hypersensitivity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Park, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SK chemicals</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Clinical Research Team</name_title>
    <organization>SK Chemicals Co.,Ltd.</organization>
  </responsible_party>
  <keyword>Healthy Male subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

